提供治疗方法

Blautix is a single-strain live biotherapeutic candidate in development for the treatment of IBS-C and IBS-D

Thetanix has a targeted anti-inflammatory mechanism and acts by inhibiting the activation of transcription factor NF-κB, an important intracellular mediator of inflammation.

活体生物药的本质安全性意味着我们可以将它们更快地使用在需要它们的患者上。

我们拥有端到端的生产制造能力, 可通过临床开发加速研究出候选药物.

活体生物药是一种被认可的受监管的新型药物.